GLP-1s have reshaped obesity treatment and healthcare in 2023. What's next in 2024? Accolade's report unpacks trends, costs, and HR insights to help guide employers toward understanding their role in the care continuum of treating obesity
In 2023, GLP-1 medications have stormed the healthcare scene as a treatment for obesity. But what does 2024 hold? Our report dives into the shifting attitudes of benefits planners towards these treatments. Discover key insights from HR decision-makers, explore cost implications, and understand the rising demand for trusted information.
Are you prepared to optimize your benefits package for an increasingly health-conscious world? Get ahead with Accolade’s comprehensive employee health trends report.
HR can help overwhelmed employees get care when it matters most. New health trends report explores causes of stress and offers solutions, including virtual care expansion and enhanced health equity...
Read nowA survey conducted by Savanta shows Accolade services improve the employee’s experience and perception of both their health plan and employer...
Read nowAccolade’s personalized advocacy solution sets itself apart from competition.
Read now
